Literature DB >> 16504349

An in vitro immune response model to determine tetanus toxoid antigen (vaccine) specific immunogenicity: Selection of sensitive assay criteria.

Sytse J Piersma1, Marlies P P A M Leenaars, Laurence Guzylack-Piriou, Artur Summerfield, Coenraad F M Hendriksen, Ken C McCullough.   

Abstract

Many vaccines employed in childhood vaccination programmes are produced by conventional techniques, resulting in complex biological mixtures for which batch-related quality control requires in vivo potency testing. Monitoring consistency via in vitro tests during the vaccine production has the capacity to replace certain of the in vivo methods. In this respect, determining vaccine antigen immunogenicity through functional immunological tests has high potential. Advances in immunology have made it possible to analyse this biological activity by in vitro means. The present study established such an in vitro test system for tetanus toxoid (TT). This measured vaccine immunogenicity through an antigen-specific secondary (recall) response in vitro, using a porcine model growing in value for its closeness to human immune response characteristics. Discrimination between the specific recall TT antigen and diphtheria toxoid (DT) was possible using both peripheral blood mononuclear cell cultures and monocyte-derived dendritic cells in co-culture with autologous specific lymphocytes. TT-specific activation was detected with highest discrimination capacity using proliferation assays, as well as IFN-gamma and TT-specific antibody ELISPOTS (measuring secreting T and B lymphocytes, respectively). These in vitro systems show a high potential for replacing animal experimentation to evaluate the immunogenicity of complex vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504349     DOI: 10.1016/j.vaccine.2006.01.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Submicroscopic Plasmodium infection during pregnancy is associated with reduced antibody levels to tetanus toxoid.

Authors:  C Álvarez-Larrotta; O M Agudelo; Y Duque; K Gavina; S K Yanow; A Maestre; J Carmona-Fonseca; E Arango
Journal:  Clin Exp Immunol       Date:  2018-10-19       Impact factor: 4.330

2.  A Modular Vaccine Platform Combining Self-Assembled Peptide Cages and Immunogenic Peptides.

Authors:  Caroline Morris; Sarah J Glennie; Hon S Lam; Holly E Baum; Dhinushi Kandage; Neil A Williams; David J Morgan; Derek N Woolfson; Andrew D Davidson
Journal:  Adv Funct Mater       Date:  2019-01-11       Impact factor: 18.808

3.  Non-animal replacement methods for veterinary vaccine potency testing: state of the science and future directions.

Authors:  Jodie Kulpa-Eddy; Geetha Srinivas; Marlies Halder; Richard Hill; Karen Brown; James Roth; Hans Draayer; Jeffrey Galvin; Ivo Claassen; Glen Gifford; Ralph Woodland; Vivian Doelling; Brett Jones; William S Stokes
Journal:  Procedia Vaccinol       Date:  2011-12-23

Review 4.  The porcine dendritic cell family.

Authors:  Artur Summerfield; Kenneth C McCullough
Journal:  Dev Comp Immunol       Date:  2008-06-06       Impact factor: 3.636

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.